{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:52:28Z","timestamp":1775487148428,"version":"3.50.1"},"reference-count":23,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2021,9,10]]},"DOI":"10.1253\/circrep.cr-21-0084","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T22:11:16Z","timestamp":1628287876000},"page":"504-510","source":"Crossref","is-referenced-by-count":3,"title":["Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation After Stent Implantation in a Rabbit Arteriovenous Shunt Model"],"prefix":"10.1253","volume":"3","author":[{"given":"Sho","family":"Torii","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Major in Integrative Bioscience and Biomedical Engineering, Waseda University Graduate School of Science and Engineering"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ijichi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhiro","family":"Sugidachi","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Ikari","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokai University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaku","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kindai University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: Stent Anticoagulation Restenosis Study Investigators. <i>N Engl J Med<\/i> 1998; 339: 1665\u20131671.","DOI":"10.1056\/NEJM199812033392303"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sutton NR, Seth M, Ruwende C, Gurm HS. Outcomes of patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>J Am Coll Cardiol<\/i> 2016; 68: 895\u2013904.","DOI":"10.1016\/j.jacc.2016.05.085"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. <i>N Engl J Med<\/i> 2019; 380: 1509\u20131524.","DOI":"10.1056\/NEJMoa1817083"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. <i>Lancet<\/i> 2013; 381: 1107\u20131115.","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. <i>N Engl J Med<\/i> 2017; 377: 1513\u20131524.","DOI":"10.1056\/NEJMoa1708454"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. <i>N Engl J Med<\/i> 2016; 375: 2423\u20132434.","DOI":"10.1056\/NEJMoa1611594"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, Phase 3b trial. <i>Lancet<\/i> 2019; 394: 1335\u20131343.","DOI":"10.1016\/S0140-6736(19)31872-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nakamura M, Kimura K, Kimura T, Ishihara M, Otsuka F, Kozuma K, et al. JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. <i>Circ J<\/i> 2020; 84: 831\u2013865.","DOI":"10.1253\/circj.CJ-19-1109"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: A subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Am Heart J<\/i> 2014; 168: 303\u2013309.","DOI":"10.1016\/j.ahj.2014.06.005"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. <i>N Engl J Med<\/i> 2019; 381: 1524\u20131534.","DOI":"10.1056\/NEJMoa1908973"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>N Engl J Med<\/i> 2009; 361: 1045\u20131057.","DOI":"10.1056\/NEJMoa0904327"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. <i>Circ J<\/i> 2014; 78: 1684\u20131692.","DOI":"10.1253\/circj.CJ-13-1482"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. <i>JAMA<\/i> 2019; 321: 2414\u20132427.","DOI":"10.1001\/jama.2019.8145"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. <i>Circulation<\/i> 2011; 123: 1400\u20131409.","DOI":"10.1161\/CIRCULATIONAHA.110.003210"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Torii S, Jinnouchi H, Sakamoto A, Kutyna M, Cornelissen A, Kuntz S, et al. Drug-eluting coronary stents: Insights from preclinical and pathology studies. <i>Nat Rev Cardiol<\/i> 2019; 17: 37\u201351.","DOI":"10.1038\/s41569-019-0234-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Torii S, Cheng Q, Mori H, Lipinski MJ, Acampado E, Perkins LEL, et al. Acute thrombogenicity of fluoropolymer-coated versus biodegradable and polymer-free stents. <i>EuroIntervention<\/i> 2019; 14: 1685\u20131693.","DOI":"10.4244\/EIJ-D-17-00728"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lipinski MJ, Acampado E, Cheng Q, Adams L, Torii S, Gai J, et al. Comparison of acute thrombogenicity for magnesium versus stainless steel stents in a porcine arteriovenous shunt model. <i>EuroIntervention<\/i> 2019; 14: 1420\u20131427.","DOI":"10.4244\/EIJ-D-17-00958"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Jinnouchi H, Kutyna M, Torii S, Cheng Q, Sakamoto A, Guo L, et al. Comparison of acute thrombogenicity and albumin adsorption in three different durable polymer coronary drug-eluting stents. <i>EuroIntervention<\/i> 2021; 17: 248\u2013256.","DOI":"10.4244\/EIJ-D-19-00938"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J<\/i> 2018; 39: 213\u2013260.","DOI":"10.1093\/eurheartj\/ehx419"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, et al. Optical coherence tomography findings in patients with coronary stent thrombosis: A report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort). <i>Circulation<\/i> 2017; 136: 1007\u20131021.","DOI":"10.1161\/CIRCULATIONAHA.117.026788"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Torii S, Jinnouchi H, Sakamoto A, Mori H, Park J, Amoa FC, et al. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: Impact on healing. <i>Eur Heart J<\/i> 2020; 41: 786\u2013796.","DOI":"10.1093\/eurheartj\/ehz850"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Torii S, Nakazawa G, Ijichi T, Yoshikawa A, Ohno Y, Ikari Y. Comparison of the endothelial coverage in everolimus and zotarolimus-eluting stents in normal, atherosclerotic, and bifurcation rabbit iliac arteries. <i>Cardiovasc Interv Ther<\/i> 2018; 33: 55\u201361.","DOI":"10.1007\/s12928-016-0437-6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. <i>Circulation<\/i> 2020; 141: 781\u2013783.","DOI":"10.1161\/CIRCULATIONAHA.119.044584"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/3\/9\/3_CR-21-0084\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T03:33:09Z","timestamp":1631331189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/3\/9\/3_CR-21-0084\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-21-0084","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"article-number":"CR-21-0084"}}